Cardioprotective effects of a selective B 2 receptor agonist of bradykinin post-acute myocardial infarct

American Journal of Hypertension

Volumn 23, Issue 5, 2010, Pages 562-568

  Marketou, Maria ^a   Kintsurashvili, Ekaterina ^a,b   Papanicolaou, Kyriakos N ^a   Lucero, Hector A ^a,b   Gavras, Irene ^a   Gavras, Haralambos ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Alapis Research Laboratories Inc   (United States)

Author keywords

Blood pressure; Bradykinin analogue; Cardiac function; Cardiac remodeling; Hypertension; Myocardial ischemia

Indexed keywords

BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR AGONIST; COMPLEMENTARY DNA; NG 291; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR EFFECT; DRUG EFFECT; GENE EXPRESSION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART PROTECTION; HEART WEIGHT; HISTOLOGY; MALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; APOPTOSIS; BLOOD PRESSURE; BRADYKININ; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; MALE; MICE; MICE, INBRED STRAINS; MYOCARDIAL INFARCTION; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE III; NUCLEAR PROTEINS; RECEPTOR, BRADYKININ B2; STROKE VOLUME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951136034     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2010.20     Document Type: Article

References (46)

1. Gavras H. Corcoran Lecture. Angiotensin-converting enzyme inhibition and the heart. Hypertension 1994; 23:813-818.
2. Erdös EG. The ACE and I: how ACE inhibitors came to be. FASEB J 2006; 20: 1034-1038.
3. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980; 32:1-46.
4. Regoli DC, Marceau F, Lavigne J. Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol 1981; 71:105-115.
5. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 1998; 50:357-386.
6. Benetos A, Gavras H, Stewart JM, Vavrek RJ, Hatinoglou S, Gavras I. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension 1986; 8:971-974.
7. Ruocco NA, Bergelson BA, Yu TK, Gavras I, Gavras H. Augmentation of coronary blood flow by ACE inhibition: role of angiotensin and bradykinin. Clin Exp Hypertens 1995; 17:1059-1072.
8. Martorana PA, Kettenbach B, Breipohl G, Linz W, Schölkens BA. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 1990; 182:395-396.
9. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993; 21:996-1003.
10. Liu YH, Yang X P, Sharov VG, Sigmon DH, Sabbath HN, Carretero OA. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia\reperfusion injury in rats. Hypertension 1996; 27:7-13.
11. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Furukawa L, Asagami T, Hino T, Saito F, Otsuka Y. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 1994; 23:450-455.
12. Kohlman O Jr, Neves Fde A, Ginoza M, Tavares A, Cezaretti ML, Zanella MT, Ribeiro AB, Gavras I, Gavras H. Role of bradykinin in insulin sensitivity and blood pressure regulation during hyperinsulinemia. Hypertension 1995; 25:1003-1007.
13. Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, Gavras H. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 2001; 38: 1355-1360.
14. Alfie ME, Yang X P, Hess F, Carretero OA. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 1996; 224:625-630.
15. Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis M P, Glorioso N, Dessì-Fulgheri P, Sarzani R, Anania V. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 1997; 96:3570-3578.
16. Yang X P, Liu YH, Scicli GM, Webb CR, Carretero OA. Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia\reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 1997; 30:735-740.
17. Tschöpe C, Spillmann F, Altmann C, Koch M, Westermann D, Dhayat N, Dhayat S, Bascands JL, Gera L, Hoffmann S, Schultheiss H P, Walther T. The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. Cardiovasc Res 2004; 61:559-569.
18. Duka A, Kintsurashvili E, Duka I, Ona D, Hopkins TA, Bader M, Gavras I, Gavras H. Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension 2008; 51:1352-1357.
19. Lagneux C, Bader M, Pesquero JB, Demenge P, Ribuot C. Detrimental implication of B1 receptors in myocardial ischemia: evidence from pharmacological blockade and gene knockout mice. Int Immunopharmacol 2002; 2:815-822.
20. Bélanger S, Bovenzi V, Côté J, Neugebauer W, Amblard M, Martinez J, Lammek B, Savard M, Gobeil F Jr. Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor. Peptides 2009; 30:777-787.
21. Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, Izumo S. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol Genomics 2004; 16:349-360.
22. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 1995; 25:1111-1115.
23. Johns C, Gavras I, Handy DE, Salomao A, Gavras H. Models of experimental hypertension in mice. Hypertension 1996; 28:1064-1069.
24. Yang X P, Liu YH, Rhaleb NE, Kurihara N, Kim HE, Carretero OA. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol 1999; 277:H1967-H1974.
25. Linz W, Wiemer G, Schölkens BA. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies. Diabetes 1996; 45 Suppl 1: S51-S58.
26. Tio RA, Tobé TJ, Bel KJ, de Langen CD, van Gilst WH, Wesseling H. Beneficial effects of bradykinin on porcine ischemic myocardium. Basic Res Cardiol 1991; 86:107-116.
27. Yao YY, Yin H, Shen B, Chao L, Chao J. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept 2007; 140:12-20.
28. Wollert KC, Studer R, Doerfer K, Schieffer E, Holubarsch C, Just H, Drexler H. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation 1997; 95:1910-1917.
29. Silva JA Jr, Araujo RC, Baltatu O, Oliveira SM, Tschöpe C, Fink E, Hoffmann S, Plehm R, Chai KX, Chao L, Chao J, Ganten D, Pesquero JB, Bader M. Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J 2000; 14:1858-1860.
30. Pinto YM, Bader M, Pesquero JB, Tschöpe C, Scholtens E, van Gilst WH, Buikema H. Increased kallikrein expression protects against cardiac ischemia. FASEB J 2000; 14:1861-1863.
31. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47:25-49.
32. Hu K, Gaudron P, Anders HJ, Weidemann F, Turschner O, Nahrendorf M, Ertl G. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res 1998; 39: 401-412.
33. Tanaka Y, Nagai M, Date T, Okada T, Abe Y, Seki S, Taniguchi M, Taniguchi I, Mochizuki S. Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats. Hypertens Res 2004; 27:865-875.
34. Wang LX, Ideishi M, Yahiro E, Urata H, Arakawa K, Saku K. Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia\reperfusion-induced myocardial injury. Hypertens Res 2001; 24:179-187.
35. Yin H, Chao J, Bader M, Chao L. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides 2007; 28:1383-1389.
36. Ito H, Hayashi I, Izumi T, Majima M. Bradykinin inhibits development of myocardial infarction through B2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats. Br J Pharmacol 2003; 138:225-233.
37. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-241.
38. Zhao X, He G, Chen YR, Pandian R P, Kuppusamy P, Zweier JL. Endothelium-derived nitric oxide regulates postischemic myocardial oxygenation and oxygen consumption by modulation of mitochondrial electron transport. Circulation 2005; 111:2966-2972.
39. Zhao X, Chen YR, He G, Zhang A, Druhan LJ, Strauch AR, Zweier JL. Endothelial nitric oxide synthase (NOS3) knockout decreases NOS2 induction, limiting hyperoxygenation and conferring protection in the postischemic heart. Am J Physiol Heart Circ Physiol 2007; 292:H1541-H1550.
40. Schwartz F, Duka A, Duka I, Cui J, Gavras H. Novel targets of ANG II regulation in mouse heart identified by serial analysis of gene expression. Am J Physiol Heart Circ Physiol 2004; 287:H1957-H1966.
41. Duka A, Schwartz F, Duka I, Johns C, Melista E, Gavras I, Gavras H. A novel gene (Cmya3) induced in the heart by angiotensin II-dependent but not salt-dependent hypertension in mice. Am J Hypertens 2006; 19:275-281.
42. McCalmon SA, Desjardins DM, Ahmad S, Davidoff KS, Snyder CM, Sato K, Ohashi K, Kielbasa OM, Mathew M, Ewen E P, Walsh K, Gavras H, Naya FJ. Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target gene Xirp2. Circ Research 2010; e-pub ahead of print 21 January 2010.
43. Feuvray D, Darmellah A. Diabetes-related metabolic perturbations in cardiac myocyte. Diabetes Metab 2008; 34 Suppl 1:S3-S9.
44. Sato M, Engelman RM, Otani H, Maulik N, Rousou JA, Flack JE 3rd, Deaton DW, Das DK. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. Circulation 2000; 102:III346-III351.
45. Heitsch H. The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease. Expert Opin Investig Drugs 2003; 12:759-770.
46. Faussner A, Bathon JM, Proud D. Comparison of the responses of B1 and B2 kinin receptors to agonist stimulation. Immunopharmacology 1999; 45:13-20.